Nasdaq:US$15.21 (+0.37) | HKEX:HK$25.10 (+0.95) | AIM:£2.31 (+0.11)
Search Result
Previous Article   |   Next Article
Announcements & Press Releases, Oncology / Immunology | 17 Feb 2009

Chi-Med Announces Completion of Patient Enrolment in its US Phase II Crohn’s Disease Clinical Trial of HMPL-004, its Lead Anti-Inflammatory Drug Candidate

1 items
a090217